Details for Patent: 12,195,496

Which drugs does patent 12,195,496 protect, and when does it expire?

Patent 12,195,496 protects INQOVI and is included in one NDA.

This patent has twelve patent family members in ten countries.

Summary for Patent: 12,195,496

Title:	2′-deoxy-2′,2′-difluorotetrahydrouridines with high purity and methods of making the same
Abstract:	The invention relates to methods of synthesizing 2′-deoxy-2′,2′-difluorotetrahydrouridine with increased purity and uniform particle size distribution. In particular, methods of the invention include crystallization and isolation procedures rendering synthetic reaction intermediates. The invention further includes compositions comprising the final compound in highly pure form, including lower number of impurities and lower levels of individual and total impurities.
Inventor(s):	Gemma Zuend, Ian Scott, Nipun Davar, Kimiyoshi Annaka, Masahiro Miyake, Motoshi MATSUI
Assignee:	Taiho Pharmaceutical Co Ltd
Application Number:	US18/309,435
Patent Claim Types: see list of patent claims	Composition;

Drugs Protected by US Patent 12,195,496

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Taiho Oncology	INQOVI	cedazuridine; decitabine	TABLET;ORAL	212576-001	Jul 7, 2020		RX	Yes	Yes			Y

International Family Members for US Patent 12,195,496

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2020363412
Brazil	112022006523
Canada	3154754